Clinical Trials Logo

Filter by:
NCT ID: NCT03192683 Completed - Pediatric ALL Clinical Trials

Modified "Providence" Pedi Cast-Sling vs.Cast and Sling

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

Examining custom made sling vs. off the shelf sling for immobilization following pediatric upper extremity fractures.

NCT ID: NCT03198104 Completed - Liver Diseases Clinical Trials

Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI

Kids4LIFe
Start date: April 1, 2016
Phase:
Study type: Observational

This is a prospective observational study which will recruit up to 100 paediatric participants over a period of 30 months to determine whether MRI is as accurate at detecting, distinguishing, and monitoring liver disease as current standard of care techniques such as liver biopsy and fibroscan.

NCT ID: NCT03199638 Completed - Diabetes Mellitus Clinical Trials

Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

This project will assess the feasibility and efficacy of the use of exercise and dietary supplementation with a non essential amino acid - glutamine - a component of most protein supplements, on the regulation of plasma glucose homeostasis in a clinical setting of children with type 1 diabetes (T1D). The study specifically targets patients in puberty as this period is associated with a physiological decline in insulin sensitivity, the latter often associated with poor control. Although physical exercise has long been known to exert beneficial effects on metabolism, lack of time is the most common reason perceived as preventing the performance of exercise in both healthy and diabetic subjects. In earlier studies, the investigators showed that oral supplementation with glutamine, a non essential amino acid given prior to exercise decreases overnight post-exercise blood glucose in adolescents with T1D. Hence, the objective of the current study is to investigate if a novel way of exercising, such as performing 6 short bouts of just 1 min each of intense exercise ('exercise snacks') 30 min before meals, with or without glutamine, improves glycemic control in adolescents with T1D. Designing innovative ways to improve diabetes control in adolescents is highly desirable. The specific aim of the project is to determine whether the sustained use of the proposed exercise snacks with or without glutamine results in diminished glycemic variability and/or improved glucose control

NCT ID: NCT03209492 Completed - Prostate Cancer Clinical Trials

Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"

Start date: April 1, 2016
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety in patients with prostate cancer receiving the drug in the routine clinical setting.

NCT ID: NCT03209635 Completed - Immune Function Clinical Trials

Weissella Cibaria JW15 Consumption and NK Cell Activity

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

A The aim of this study was to investigate the impact of consuming Weissella cibaria (W. cibaria) JW15 supplementation isolated from Kimchi, Korea traditional fermented food, on natural killer (NK) cell activity and circulating levels of cytokines and immunoglobulin (Ig).

NCT ID: NCT03230604 Completed - Caries, Dental Clinical Trials

Clinical Performance of Two Bulk-Fill Composite of Posterior Restorations

Start date: April 1, 2016
Phase: N/A
Study type: Interventional

To minimize the effects of polymerization shrinkage in the restorative treatment, there are new composites called Bulk- Fill which the companies has developed this composites for example Tetric N Ceram(Ivoclar-Vivadent) and Filtek ( 3M ESPE). Its decreased polymerization shrinkage and properties allow the material to be inserted in one layer being quickly than traditional composite. This clinical study is designed to compare the clinical performance of the bulk fill composite resin in Class I (one-surface posterior), II (two-surface posterior) and V (cervical-surface posterior) fillings.

NCT ID: NCT03232294 Completed - Fetal Macrosomia Clinical Trials

Fetal Front-abdominal Wall Thickness and Perinatal Outcome

Start date: April 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Abnormal fetal development such as macrosomia can cause some complications on both fetus and mother.The measurement of fetal anterior abdominal wall thickness (FAWT) is an easy examination that it can be obtained during an examination of a pregnant woman by ultrasound. Macrosomia for fetus can lead to some morbidities. It can affect perinatal outcome and increase childbirth complications and operative birth. There are some studies scrutinizing the relationship between FAWT and diabetes in the literature. However there are few studies which scrutinize effect of FAWT on both abnormal fetal development and adverse perinatal outcomes in non-diabetic pregnancies and non high risk pregnancies. Hence the investigators wonder if FAWT can anticipate birth-weight or macrosomic infant or perinatal outcome regarding with macrosomia in the second trimester.

NCT ID: NCT03242304 Completed - Ischemic Stroke Clinical Trials

Neuroactive Steroids in Acute Ischemic Stroke

Cortisol
Start date: April 1, 2016
Phase: N/A
Study type: Observational

Acute ischemic stroke (AIS) represents an economical challenge for health systems all over the globe. Despite increasing knowledge of the pathophysiology of AIS, there is no satisfactory treatment to revert the resulting brain damage. Changes of neuroactive steroids have been found in different neurological diseases. In this regard, the investigators have previously demonstrated that old patients with AIS show changes of plasma cortisol and estradiol concentrations, in that increased steroid levels are associated with a deterioration of neurological status and a worse cognitive decline. The present study assessed in patients with AIS if changes of behavior, brain-derived neurotrophic factor (BDNF) and nitrites (NO-2) (nitric oxide soluble metabolite) bear a relationship with the degree of hypercortisolism. To this purpose, the investigators recruited patients hospitalized at the Central Military Hospital emergency room within the first 24 hours of AIS. Subjects were divided into two groups, each one composed of 40 control subjects and 40 AIS patients, including men and women. The neurological condition was assessed using the NIHSS and the cognitive status with the Montreal Cognitive Assessment (MoCA test). The emotional status was evaluated using the Montgomery-Asberg Depression Rating Scale (MADRS), whereas the Modified Rankin Scale (MRS) was used to determine the functional condition. BDNF and NO-2 plasma levels were measured by ELISA and the Griess reaction method, respectively.

NCT ID: NCT03252860 Completed - Clinical trials for Surgical Safety Checklist Compliance

WHO SSC : Compliance and Associated Surgical Outcomes in Uganda's Referral Hospitals

Start date: April 1, 2016
Phase: N/A
Study type: Observational

The investigators set out to determine the extent of compliance with the World Health Organization Surgical Safety Checklist and the association of this compliance with perioperative surgical outcomes in five of Uganda's referral hospitals.

NCT ID: NCT03257813 Completed - Ocular Hypertension Clinical Trials

Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

CONFORTK
Start date: April 1, 2016
Phase: Phase 3
Study type: Interventional

Aim: To demonstrate the non-inferiority of the PRO-122 ophthalmic solution manufactured by Laboratorios Sophia S.A. de C.V. versus Krytantek Ofteno® ophthalmic solution like hypotensive therapy in subjects with primary open angle glaucoma or ocular hypertension. Study design: a multicentric, prospective, crossover (2x2), double blind clinical study. Sample size: one hundred patients with primary open angle glaucoma or ocular hypertension. Patients in the period 1: In the first sequence 30 patients will be assigned to receive the ophthalmic solution: Krytantek Ofteno ® (timolol 0.5%%/brimonidine 0.2%/dorzolamide 2%) 1 drop B.I.D. during 30 days and the second sequence 30 patients will be assigned to receive the ophthalmic solution: PRO-122 1 drop B.I.D. during 30 days in the same period. Washout period: 20 hours. Patients in the period 2: the pharmacological intervention change to the opposite therapy for 30 days